Multimodal Biomarkers Enhance Parkinsonian Syndrome Diagnosis

Enhancing Diagnostic Clarity in Parkinsonian Syndromes

The differential diagnosis of neurodegenerative parkinsonian syndromes, including Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy, remains a significant clinical challenge due to their overlapping motor and non-motor symptoms [1]. This clinical ambiguity can delay accurate diagnosis and appropriate management. While neuroimaging techniques provide valuable information, they often lack the specificity to definitively distinguish these conditions, especially in early stages or when mixed pathologies are present [2, 3]. Although advanced computational methods are being explored to improve diagnostic precision [4, 5], a pressing need exists for accessible, biologically-based biomarkers that can reliably differentiate these complex disorders and guide clinical decision-making [6].

Addressing Diagnostic Challenges with a Multimodal Strategy

A new study confronts the diagnostic uncertainty in parkinsonian syndromes, which is often driven by overlapping clinical signs and the frequent presence of co-pathology, where multiple abnormal proteins accumulate in the brain. These factors can confound the interpretation of biomarkers targeting a single protein. To address this, researchers evaluated a multimodal strategy using three distinct, minimally invasive biomarkers. The first two are seed amplification assays (SAAs) performed on dermal tissue from a simple skin biopsy. This technique acts like a biological photocopier, amplifying minute quantities of misfolded proteins to detectable levels. One assay targeted alpha-synuclein, the protein aggregate characteristic of synucleinopathies like Parkinson's disease, while the other targeted 4-repeat tau, a protein isoform central to tauopathies like progressive supranuclear palsy. The third component was serum neurofilament light chain (NfL), a protein released from damaged axons that can be measured in a blood sample, serving as a general indicator of neuroaxonal injury.

Study Design and Participant Cohorts

The investigation was grounded in a prospective cohort of 166 participants, which included 40 individuals with Parkinson's disease, 29 with multiple system atrophy, 77 with progressive supranuclear palsy (PSP), and 20 healthy controls to provide a non-diseased baseline. To ensure the findings were not unique to this initial group, the researchers validated their results in a separate, independent cohort of 63 participants. This external validation is a critical step to confirm that the biomarker strategy performs reliably across different patient populations, strengthening the potential for its broader clinical application.

Individual Biomarker Performance in Differential Diagnosis

When evaluated individually, each biomarker provided distinct diagnostic information. The dermal alpha-synuclein SAA identified synucleinopathies with high sensitivity. However, it was also positive in a subset of participants with progressive supranuclear palsy (PSP), a finding consistent with known alpha-synuclein co-pathology in this primarily tau-driven disease. In contrast, the dermal 4-repeat tau SAA was highly specific for its target, identifying PSP with both high sensitivity and high specificity. This suggests it is a robust tool for confirming a PSP diagnosis. The third marker, serum neurofilament light chain (NfL), proved useful for differentiating between the two synucleinopathies, as it could distinguish multiple system atrophy from Parkinson's disease. Furthermore, in patients with PSP, serum NfL levels correlated with disease severity, indicating its potential value as a prognostic tool or for monitoring disease progression.

Enhanced Discrimination Through Biomarker Integration

The study's primary finding is that the synergy of these biomarkers provides a more powerful diagnostic tool than any single marker alone. The authors report that integrating the complementary biomarkers improved diagnostic discrimination compared with individual markers. This integrated approach allows for a more confident differentiation of Parkinson's disease, multiple system atrophy, and PSP by combining the strengths of each test. For instance, a positive 4-repeat tau SAA strongly points to PSP, while NfL levels can help distinguish multiple system atrophy from Parkinson's disease in cases where the tau assay is negative. This approach also revealed a deeper layer of biological heterogeneity within a single diagnosis. Specifically, the multimodal analysis enabled further stratification within the PSP cohort. This ability to subgroup patients based on their distinct biomarker profiles, such as the presence or absence of alpha-synuclein co-pathology, may have significant clinical implications for prognosis and the future development of targeted therapies. These findings support a move toward a biologically informed diagnosis for parkinsonian syndromes, grounding clinical classification in the specific molecular pathology of the individual patient.

References

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017. doi:10.1212/wnl.0000000000004058

2. Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging. 2020. doi:10.1007/s00259-020-04817-8

3. Nobili F, Arbizu J, Bouwman FH, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology. 2018. doi:10.1111/ene.13728

4. Rana MS, Longa FEA, Riaz A, Alamu OS. Artificial Intelligence in Early Diagnosis of Neurodegenerative Disorders: A Systematic Review of Clinical Applications and Challenges. International Journal of Medical and Health Research. 2025. doi:10.61424/ijmhr.v3i3.382

5. Xue C, Kowshik SS, Lteif D, et al. AI-based differential diagnosis of dementia etiologies on multimodal data. Nature Medicine. 2024. doi:10.1038/s41591-024-03118-z

6. Martinez-Valbuena I, Emamikhah M, Olszewska DA, et al. A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.. Nature medicine. 2026. doi:10.1038/s41591-026-04398-3